The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

Bezawit A Woldemeskel; Andrew H Karaba; Caroline C Garliss; Evan J Beck; Kristy H Wang; Oliver Laeyendecker; Andrea L Cox; Joel N Blankson

doi:10.1093/cid/ciab648

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

Clin Infect Dis. 2022 Apr 9;74(7):1268-1270. doi: 10.1093/cid/ciab648.

Authors

Bezawit A Woldemeskel¹, Andrew H Karaba¹, Caroline C Garliss¹, Evan J Beck², Kristy H Wang¹, Oliver Laeyendecker², Andrea L Cox¹, Joel N Blankson¹

Affiliations

¹ Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.
² Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA.

Abstract

Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.

Keywords: COVID; PLWH; SARS-CoV-2; mRNA vaccine.

Publication types

Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19* / prevention & control
HIV
HIV Infections*
Humans
Immunity, Cellular
Immunity, Humoral
SARS-CoV-2
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Viral
Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine